Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

/PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion...

Related Keywords

China ,Adi Raval ,Paula Dowdy ,Christine Roth ,Richard Kennedy ,Exchange Commission ,Instagram ,European Union ,Illumina Inc ,Biomarker Development ,European Society For Medical Oncology ,Almac Diagnostic Services ,Senior Vice President ,General Manager ,Middle East ,Executive Committee ,Pharmaceuticals Division ,Oncology Strategic Business ,Professor Richard Kennedy ,Medical Director ,Almac Diagnostic ,Trusight Oncology Comprehensive ,Sight Oncology Comprehensive ,Tumor Mutational Burden ,Microsatellite Instability ,Companion Diagnostics ,European Society ,Medical Oncology ,Neurotrophic Tyrosine Receptor Kinase ,Illumina ,Nc ,